Our data,
showing significantly lower plasma MCP-1 by EGCG treatment
in high-fat–fed mice, suggest that EGCG-mediated decreases in
mesenteric and retroperitoneal adipose tissue weight may play a
role in the effects of EGCG on high-fat–induced inflammation
and the development of metabolic syndrome.